KIF23 and hepatocellular carcinoma: Several studies have shown that KIF23 overexpression assessed by cDNA microarray or by quantitative reverse transcription-polymerase chain reaction (PCR) was recently shown in lung cancer, breast cancer, gliomas, paclitaxel-resistant gastric cancer, hepatocellular carcinomas, and pancreatic cancer [16, 17].